降低患有COPD的老年人落风险:试点研究测试了与虚拟护理支持的家庭炼计划的有效性
Amanda Bates1,2, Susan Furber1,3, Heidi Gilchrist2,4
1Health Promotion Service, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia.
International journal of chronic obstructive pulmonary disease
|September 17, 2025
概括
患有慢性阻塞性肺病 (COPD) 的老年人可以通过在家做炼计划来改善平衡和力量. 这项试点研究表明该计划是可行的和可接受的,表明它可以减少这一群体的跌倒风险.
科学领域:
- 老年学是一门学科.
- 肺部病理学 肺部病理学
- 康复科学 康复科学 康复科学
背景情况:
- 与同龄人相比,COPD的老年人面临着较高的跌倒风险.
- 基于家庭的炼计划为改善老年人的平衡和力量提供了可行的解决方案.
- 虚拟护理提供模式可以提高COPD患者的可访问性.
研究的目的:
- 试点测试一个为期6个月的家庭平衡和力量炼计划,适用于50岁及以上的COPD患者.
- 评估该计划对强度,平衡和跌倒风险的影响.
- 在虚拟护理环境中评估该计划的可行性和可接受性.
主要方法:
- 一项试点研究涉及50岁以上的患有COPD的成年人,他们获得了虚拟护理.
- 参与者参加了为期6个月的家庭炼计划,重点是平衡和力量.
- 使用短物理性能电池 (SPPB) 和替代步骤测试,以及跌倒史和程序可接受性调查来测量结果.
主要成果:
- 从基线到6个月 (效果大小2.01) 和3到6个月 (效果大小1.65) 之间,从基线到6个月的SPPB得分中观察到显著的改善.
- 替代步骤测试显示,3个月后3秒以上 (效果大小-3.30) 和6个月后4秒 (效果大小-4.01) 的显著改善.
- 该计划表现出高度的可接受性和可行性,参与者打算继续练习并推该计划.
结论:
- 通过虚拟护理提供的家庭炼计划显著改善了COPD老年人的力量和平衡.
- 尽管完成炼的频率低于推,但参与者表现出可衡量的收益.
- 该计划是可以接受的,可行的,并显示出降低该人口中跌倒风险的潜力.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
737
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
737
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Peripheral Artery Disease III: Interprofessional Care
248
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
248
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Chronic Obstructive Pulmonary Disease-V: Nursing Management
5.1K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
5.1K


